NM8074 for relapsed or resistant atypical HUS with kidney injury
Treatments studied
Part of Blood & lymphatic, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 study tests NM8074, a medicine that targets the immune system’s complement pathway, to treat atypical HUS (aHUS) that is coming back or not responding well. It may help stop ongoing blood vessel damage and improve blood counts and kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18 or older when you sign consent
- Your atypical HUS must be relapsed or resistant and still active, with signs like low platelets, blood cell breakdown (hemolysis), and ongoing microangiopathy
- You must have evidence of ongoing blood vessel damage and acute kidney injury (for example, abnormal kidney tests or reduced kidney filtering)
- Blood test results must show low platelets, anemia from hemolysis, and an LDH level at least 1.5 times normal
- Before the first dose, you must complete meningococcal vaccines (MenACWY and MenB); if timing is too short, you must take preventive antibiotics
- You must be able to follow study visits and rules, including contraception/pregnancy requirements
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how well and how safely NM8074 works for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not recently received a similar “complement inhibitor” medicine. It may help reduce PNH-related blood cell breakdown and anemia, and it will closely monitor side effects.
This study tests a new drug called NM8074 for people with ANCA-associated vasculitis, a condition where the immune system attacks blood vessels. It aims to see if the drug can help control the disease when used with standard treatments like cyclophosphamide or rituximab.
This early-phase study tests whether NM8074 can help adults with C3 glomerulopathy. It focuses on people with low blood C3 levels and protein in the urine, and it includes close monitoring and required vaccinations to reduce infection risk.
This trial tests an experimental medicine called NM8074 for people with IgA nephropathy, a type of kidney disease. It aims to see if NM8074 can help protect your kidneys and reduce damage.
This Phase 2 trial studies NM8074 in adults with paroxysmal nocturnal hemoglobinuria (PNH) whose blood counts and breakdown of red blood cells (hemolysis) are not controlled enough on Soliris. NM8074 is meant to reduce the abnormal immune “complement” activity driving the disease and its symptoms like anemia.
This Phase 2 trial studies NM8074 in people with paroxysmal nocturnal hemoglobinuria (PNH) who are already taking Soliris. It aims to improve PNH control by targeting the disease while you stay on your current Soliris treatment.
Hear when a new aHUS - Atypical Hemolytic Uremic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.